IFF bows out on H&R
This article was originally published in The Rose Sheet
Executive Summary
Fragrance and flavors supplier is not likely to make formal bid for Bayer's Harrmann & Reimer fragrance and flavors division and does not "anticipate any acquisition activity in the short-term," CEO Richard Goldstein says during the company's annual meeting May 7. "We did look at H&R, and at the moment, my view is that we've got enough on our plate," exec notes. Givaudan and Dutch chemical supply company Degussa are among those interested in acquiring the business; sale is expected to be complete by summer (1"The Rose Sheet" April 22, 2002, In Brief)...
You may also be interested in...
Haarmann & Reimer sale
As many as seven or eight parties are bidding for Harrmann & Reimer fragrance & flavors division, Bayer says. German specialty chemicals group Degussa, Swiss fragrance supplier Givaudan and institutional investors are among those who have entered non-binding bids for the business, company reports. Bayer, which is selling H&R to focus on its chemicals business, is on track to complete sale by summer ( 1"The Rose Sheet" March 18, 2002, In Brief)...
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.